Akeso Inc. (9926.HK) ("Akeso", "the Company") released its 2024 annual report, emphasizing the company's key achievements in drug research, clinical development, and commercialization.
Dr. Cesar Rodriguez discussed treatment advancements for multiple myeloma during a CURE Educated Patient® Summit.
An antibody discovery platform revealed more than 60 monoclonal antibodies specific to patients with alpha-gal syndrome, ...
Today, the U.S. Food and Drug Administration approved Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of ...
Clinical Trials Arena on MSN4d
Helicore doses first subject in Phase I trial of obesity treatmentHelicore Biopharma has dosed the first subject in the randomised first-in-human Phase I trial of HCR-188 to treat obesity.
An immune system defect makes affected individuals vulnerable to severe viral diseases such as influenza or COVID-19. It is ...
Checkpoint Therapeutics, Inc. ("Checkpoint”) (Nasdaq: CKPT), a commercial-stage immunotherapy and targeted oncology company, ...
For the study, the researchers gave the study participants an experimental anti-amyloid drug. They found that 22 participants ...
News Medical on MSN6d
Study reveals new antibody treatment for flesh eating fungus infectionA new study offers hope in the fight against flesh-eating fungus infections. Researchers have discovered a promising antibody ...
Radiopharm Theranostics Limited targets oncology with radiotherapeutics like Lu-RAD204 for NSCLC. Key 2025 data signals ...
The Food and Drug Administration has approved more than 100 monoclonal antibodies to treat a range of diseases. Other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback